Detalles de la búsqueda
1.
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.
J Am Soc Nephrol
; 35(3): 347-360, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38147137
2.
The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial.
Am J Transplant
; 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38387622
3.
Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial.
J Am Soc Nephrol
; 34(1): 145-159, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36195441
4.
Burden of neutropenia and leukopenia among adult kidney transplant recipients: A systematic literature review of observational studies.
Transpl Infect Dis
; 25(1): e14000, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36508475
5.
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
JAMA
; 330(1): 33-42, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37279999
6.
Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia.
Clin Transplant
; 36(4): e14583, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984735
7.
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
J Am Soc Nephrol
; 32(12): 3252-3264, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34706967
8.
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial.
Am J Transplant
; 21(7): 2543-2554, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331082
9.
Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
Am J Transplant
; 21(5): 1691-1698, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33128812
10.
A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
Am J Transplant
; 20(1): 172-180, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31397943
11.
The impact of belatacept on the phenotypic heterogeneity of renal T cell-mediated alloimmune response: The critical role of maintenance treatment and inflammatory load.
Clin Transplant
; 34(11): e14084, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32939817
12.
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Am J Transplant
; 19(11): 3018-3034, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31152476
13.
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Am J Transplant
; 19(11): 3035-3045, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31257724
14.
Belatacept and Long-Term Outcomes in Kidney Transplantation.
N Engl J Med
; 374(4): 333-43, 2016 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-26816011
15.
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Clin Transplant
; 33(3): e13487, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30689221
16.
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
J Am Soc Nephrol
; 29(7): 1979-1991, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29752413
17.
Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet.
Am J Transplant
; 23(10): 1483-1484, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37394381
18.
A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
Am J Transplant
; 18(12): 2945-2954, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29745007
19.
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
Clin Transplant
; 32(4): e13225, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29461660
20.
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Am J Kidney Dis
; 69(5): 587-594, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27889299